Announcements Trials
Browse Landscape

Phase

Phase 1 24Phase 2 23Phase 3 7Phase 1/2 5Phase EARLY_PHASE1 2Phase 4 2Phase NA 1

Status

Completed 7Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Dermatologic 7

Conditions

Melanoma 7Neoplasms 2Skin Neoplasms 1Skin Diseases 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Completed × Vemurafenib × Clear all
NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Hoffmann-La Roche

Phase 3 Completed
514 enrolled 25 charts 1 FDA
Dermatologic

Melanoma

NCT01689519 2022-05-02

coBRIM

Hoffmann-La Roche

Phase 3 Completed
495 enrolled 15 charts
Dermatologic

Melanoma

NCT01597908 2021-02-24

COMBI-v

Novartis

Phase 3 Completed
704 enrolled 13 charts
Dermatologic

Melanoma, Neoplasms

NCT01667419 2019-07-23

BRIM8

Hoffmann-La Roche

Phase 3 Completed
498 enrolled 16 charts
Dermatologic

Melanoma

NCT01307397 2017-12-18

A Study of Vemurafenib in Participants With Metastatic Melanoma

Hoffmann-La Roche

Phase 3 Completed
3,219 enrolled 21 charts
Dermatologic

Melanoma

NCT01006980 2016-09-28

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Hoffmann-La Roche

Phase 3 Completed
675 enrolled 14 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡